{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-066986","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.010537+00:00","generated_at":"2026-05-18T08:43:52.120800+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ironwood dismisses EY as auditor; appoints KPMG; prior adverse ICFR opinion cited","bullets":["Dismissed Ernst & Young as independent auditor on July 3, 2025; no disagreements during fiscal 2023 and 2024.","EY's report on internal controls for fiscal 2024 contained adverse opinion due to material weaknesses in entity-level and ITGC controls.","Material weaknesses also impacted financial close process and expenditure controls; no restatement required.","Audit Committee appointed KPMG as new independent auditor effective immediately for FY 2025.","EY agreed with disclosures; furnished letter to SEC dated July 10, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-066986","json":"https://secwatch.observer/filing/0001104659-25-066986.json","markdown":"https://secwatch.observer/filing/0001104659-25-066986.md","text":"https://secwatch.observer/filing/0001104659-25-066986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925066986/0001104659-25-066986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925066986/tm2520217d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:43:52.120800+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1300eb64d9a457dd97f551602fcf03ffb569a85","claim":"IRONWOOD PHARMACEUTICALS INC dismissed Ernst & Young LLP as its auditor.","evidence_excerpt":"On July 3, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925066986/0001104659-25-066986-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"Ernst & Young LLP"},{"label":"Successor","value":"KPMG LLP"}],"fact_type":"auditor_change"},{"claim_id":"daae21aa692ba55db47c908d07f98c011f6ef27f","claim":"IRONWOOD PHARMACEUTICALS INC engaged KPMG LLP as its auditor.","evidence_excerpt":"On July 3, 2025, the Audit Committee approved the appointment of KPMG to serve as the Company’s new independent registered public accounting firm, effective immediately, for the fiscal year ending December 31, 2025.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465925066986/0001104659-25-066986-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"KPMG LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}